Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 10/20 | 0.41 |
| ▸ | CDK9 | P50750 | 10/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | INSR | P06213 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL89338 | 0.84 | REN (0.38) | CCNKCDK9PDGFRBPDGFRAEGFR | |
| SCHEMBL90302 | 0.83 | PDGFRB (0.38) | CCNKCDK9PDGFRBPDGFRACYP11B1 | |
| SCHEMBL89349 | 0.81 | CCNK (0.38) | CCNKCDK9PDGFRBPDGFRAEGFR | |
| SCHEMBL90675 | 0.79 | KMT2A (0.40) | CCNKCDK9PDGFRBPDGFRAEGFR | |
| SCHEMBL90434 | 0.76 | ROCK2 (0.38) | KDM4EALDH1A1BRD4ATAD2 | |
| SCHEMBL89869 | 0.75 | BRD4 (0.33) | EGFRKDM4EALDH1A1BRD4ATAD2 | |
| SCHEMBL7864023 | 0.75 | ABL1 (0.37) | PDGFRBPDGFRAALDH1A1 | |
| SCHEMBL90167 | 0.74 | SLC6A4 (0.38) | KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL90083 | 0.72 | MCHR1 (0.40) | CCNKALDH1A1BRD4ATAD2 | |
| SCHEMBL2085628 | 0.69 | MEN1 (0.43) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2420491-A1 | 3 , 5-substitued piperidine compounds as renin inhibitors | Novartis AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | CCNK 3644/4885CDK9 1800/4885PDGFRB 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.